Lumos Pharma, Inc.
LUMO
$-0.02
Change (1 day)
$4.58
Year High
$1.37
Year Low
Categories
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Earnings for Lumos Pharma, Inc. (LUMO)
Earnings in 2023 (TTM): $-34,063,000
According to Lumos Pharma, Inc.'s latest financial reports the company's current earnings (TTM) are $-34,063,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Lumos Pharma, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-34,063,000 | $-34,034,000 |
| 2022 | $-31,075,000 | $-31,062,000 |
| 2021 | $-31,066,000 | $-30,430,000 |
| 2020 | $-19,636,000 | $-5,663,000 |
| 2019 | $-42,977,000 | $-42,989,000 |
| 2018 | $-60,563,000 | $-53,595,000 |
| 2017 | $-72,510,000 | $-71,951,000 |
| 2016 | $-90,511,000 | $-85,155,000 |
| 2015 | $-33,643,000 | $-40,381,000 |
| 2014 | $117.63 M | $102.86 M |
| 2013 | $-31,050,000 | $-31,180,000 |
| 2012 | $-23,321,000 | $-23,321,000 |
| 2011 | $-18,088,000 | $-18,087,000 |
| 2010 | $-16,590,000 | $-16,213,000 |
| 2009 | $-9,798,000 | $-9,442,000 |
| 2008 | $-9,373,000 | $-9,162,000 |